Kent Pharmaceuticals Limited has been acquired by DCC Plc
Dublin-based support services company, DCC plc, has acquired 100% of Kent Pharmaceuticals Ltd., the UK's largest independent generic pharmaceuticals manufacturer, for US$93 million.
DCC is a sales, marketing, distribution and business support services company. It operates in five segments: DCC Energy, DCC SerCom, DCC Healthcare, DCC Environmental, and DCC Food & Beverage.
DCC plans to combine Kent Pharmaceuticals with its healthcare division, DCC Healthcare, to create a pharma business with aggregate revenues approaching US$247 million and to become a leader in the British and Irish generic pharmaceutical market. Mike Overy, Kent Pharmaceutical’s managing director, said: “The shareholders believe this transaction provides a fantastic opportunity to continue the growth and development of Kent Pharmaceuticals with a partner that is committed to expanding into the generic pharmaceutical market.”
Oaklins Cavendish, based in the UK, advised Kent Pharmaceuticals in this transaction. There had been a significant amount of consolidation in the sector in recent months and this deal creates a substantial UK generic pharmaceutical business with excellent international expansion opportunities.
![](/files/styles/hero_image/public/HEALTHCARE%20deal%201_0.jpg)
![](/api/deal-party-images/32991/deal-parties.png)
Talk to the deal team
Related deals
Leika Medical Equipments Ltd. has been acquired by Angus Capital
The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.
Learn morePhen’X Technologies has sold a majority stake to Ciclad
The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.
Learn moreMedis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments
Medis Medical Imaging Systems B.V., a leading cardiac imaging software company, have completed a strategic investment to further develop its revolutionary non-invasive cardiovascular imaging solution. The company has announced its collaboration with GE HealthCare (Nasdaq: GEHC), a global leader in medical technology, pharmaceutical diagnostics and innovation in digital solutions, to contribute to the advancement of precision care in the diagnosis and treatment of coronary artery disease (CAD).
Learn more